Praxis Tech, the leading payment orchestration platform for the iGaming industry, today announced its partnership with Stake, the global leader in online entertainment and iGaming. The partnership ...

Praxis Precision Medicines (PRAX) stock gain as the company speed up R&D plans for its seizure drug relutrigine following ...

Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA ...

Praxis Precision Medicines, Inc. (($PRAX)) announced an update on their ongoing clinical study. Praxis Precision Medicines, Inc. is conducting a ...

Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy DesignationKey aspects of a potential NDA application ...

Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...

Fintel reports that on November 6, 2025, Wedbush maintained coverage of Praxis Precision Medicines (NasdaqGS:PRAX) with a Underperform recommendation. Analyst Price Forecast Suggests 50.50% Upside As ...

The price target increase comes after Praxis announced topline results from both Study 1 and Study 2 of its ESSENTIAL3 trial evaluating ulixacaltamide (ulixa) in essential tremor (ET). The company ...

This is why communication has an outsized impact on engagement. Gallup finds that 70% of the variance in employee engagement ...

Sensory overload and sensory seeking describe opposite but related patterns of sensory processing, where individuals either ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. This article has ...